10th July – BioBriefing – US Regulatory Landscape: Hills and Valleys at FDA
Monday 10th July – 4:00 pm – 6:00 pm Dr Mary Beth Henderson is the Senior Principal Advisor in Regulatory Affairs and Quality Systems at US based RCRI® (Regulatory & Clinical Research Institute, Inc.). Dr Henderson will be…
2017 Connecting Women – Charity Announced!
The BioMelbourne Network Connecting Women Lunch is now fully booked with over 400 women set to attend on Friday 2nd June. We’re also delighted that we have received a record number of nominations for the BioMelbourne Network Women in Leadership…
More Access To Life-Changing Genomic Testing For Rare Diseases
More Victorian children with rare conditions and diseases will now be able to access world-leading genomic sequencing tests – at no cost – so they can get the diagnosis and treatment they need sooner. The Andrews Labor Government…
Joint statement on the Research & Development Tax Incentive (April 2017)
18 April 2017 Don’t rip the guts out of Australian medical research commercialisation Commercialisation of Australian medical research is under serious threat if the package of measures put by the ‘Ferris, Finkel, Fraser’ Review of the Research &…
Westpac Businesses of Tomorrow 2017 – Trajan Scientific and Medical Top 20
Right from our very beginning in 1817, Westpac has been guided by the same purpose: TO SUPPORT THE ECONOMIC PROGRESS OF AUSTRALIAN BUSINESSES. As we reach our 200th anniversary, that guiding purpose remains. To help the next generation…
Australia’s ProTA accelerates the development of immunotherapy to treat peanut allergy
Allergy immunotherapy company ProTA Therapeutics Pty Ltd (ProTA) will accelerate the development of a possible treatment for life-threatening peanut allergy with the appointment of its new CEO. ProTA has appointed former Mesoblast Vice President Operations Dr. Suzanne Lipe,…
Opthea Successfully Completes Placement and Institutional Entitlement Offer
• Placement and Institutional Entitlement Offer successfully completed, raising approximately A$42million with strong support from both existing and new institutional and sophisticated investors • Retail Entitlement Offer will open on Monday, 10 April 2017 and closes at 5:00pm…
Bionic Vision Technologies raises $US18m from State Path Capital, China Huarong
The Australian university-owned company in the race to develop a bionic eye to restore sight has been saved from its own near plunge into darkness after raising $US18 million ($23.6 million) from Chinese investors including the nephew of Hong…
The Medical Technologies and Pharmaceuticals (MTP) Roadmap – unlocking future growth opportunities for Australia
A changing global landscape The global MTP industry is on the cusp of enormous growth globally due to a range of factors including ageing populations, the growth of emerging markets seeking better health services and unprecedented innovation in…
New abilities to enhance cancer research at the Australian Synchrotron
It gave me great pleasure to today unveil the newest research tool that Australian scientists and researchers have in the fight against cancer. The Australian Synchrotron’s new multi-million dollar Australian Cancer Research Foundation (ACRF) Detector will fast-track new…
Easing the pain of global expansion
Two years after going global, Australian healthcare company Medical Developments International (MDI) which manufactures the acute pain killer Penthrox (commonly known as ‘the green whistle’) has opened a new facility in Melbourne Assisted by CSIRO, MDI has seen…
Opthea Launches A$45 Million Financing to Progress OPT- 302 Expanded Clinical Development
Opthea Limited (ASX:OPT) (“Opthea”), a developer of novel biologic therapies for the treatment of eye diseases, today announced the launch of an entitlement offer and institutional placement (collectively the “Offer”) to raise approximately A$45 million. Proceeds from the…
